Aaditya Khatri

TL;DR: The use of Abl kinase inhibitors might prove to be effective in the treatment of pathologies beyond leukemia and solid tumors, including neurodegenerative diseases and inflammatory pathologies.

TL;DR: It is shown that Abl kinase inhibition enhances proliferation and differentiation of a subpopulation of lung epithelial cells following pathogen-induced lung injury, resulting in dramatic expansion of an SCGB1A1+ airway cell population that coexpresses SPC, a marker for type IIAlveolar cells that promotes alveolar regeneration following bacterial pneumonia.

TL;DR: It is shown that ABL kinase allosteric inhibitors can be effectively used for the treatment of KrasG12D/+; p53−/− lung adenocarcinomas in an autochthonous mouse model, and found that treatment of tumor-bearing mice with an ABLallosteric inhibitor promoted differentiation of lungAdenocARCinomas from poorly differentiated tumors expressing basal cell markers to tumors expressing terminal differentiation markers in vivo.

TL;DR: In this article , Abel kinase allosteric inhibitors improve overall survival and impair HER2+ brain metastatic outgrowth in vivo, and they support a role for ABL kinases in the translational regulation of brain metastasis targets through Y-box-binding protein 1 (YB-1).

TL;DR: In this paper , the authors performed single-cell RNA-Seq and spatial transcriptomic analysis of explanted tissues from human lung recipients with chronic lung allograft dysfunction (CLAD) and performed independent validation studies to identify an important role of Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling in airway epithelial cells that contributes to airway-specific alloimmune injury.